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Abstract
Previous studies have demonstrated that the JC virus (JCV) late regulatory protein agnoprotein is phosphorylated by the serine/threonine-specific
protein kinase-C (PKC) and mutants of this protein at the PKC phosphorylation sites exhibit defects in the viral replication cycle. We have now
investigated whether agnoprotein phosphorylation is regulated by PP2A, a serine/threonine-specific protein phosphatase and whether JCV small t
antigen (Sm t-Ag) is involved in this regulation. Protein–protein interaction studies demonstrated that PP2A associates with agnoprotein and
dephosphorylates it at PKC-specific sites. Sm t-Ag was also found to interact with PP2A and this interaction inhibited the dephosphorylation of
agnoprotein by PP2A. The interaction domains of Sm t-Ag and agnoprotein with PP2Awere mapped, as were the interaction domains of Sm t-Ag
with agnoprotein. The middle portion of Sm t-Ag (aa 82–124) was found to be critical for the interaction with both agnoprotein and PP2A and the
N-terminal region of agnoprotein for interactionwith Sm t-Ag. To further understand the role of Sm t-Ag in JCVregulation, a stop codonwas introduced
at Ser90 immediately after splice donor site of the JCVearly gene and the functional consequences of this mutation were investigated. The ability of this
mutant virus to replicate was substantially reduced compared to WT. Next, the functional significance of PP2A in JCV replication was examined by
siRNA targeting. Downregulation of PP2A caused a significant reduction in the level of JCV replication. Moreover, the impact of Sm t-Ag on
agnoprotein phosphorylationwas investigated by creating a doublemutant of JCV,where Sm t-Ag stop codonmutant was combinedwith an agnoprotein
triple phosphorylationmutant (Ser7, Ser11 andThr21 toAla). Results showed that doublemutant behavesmuch like the triple phosphorylationmutant of
agnoprotein during viral replication cycle, which suggests that agnoprotein might be an important target of Sm t-Ag with respect to the regulation of its
phosphorylation. Collectively, these results suggest that there is an interplay between agnoprotein, Sm t-Ag and PP2Awith respect to the regulation of
JCV life cycle and this could be important for the progression of the JCV-induced disease, PML.
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One of the interesting characteristics of viruses is to use host
machinery for their own purpose in that they modify the host
system in such a way as to optimize viral replication. Recipro-
cally, some viral regulatory proteins are modified by the host
system and thereby function differently at different stages of the
infection cycle. One of the prime examples of polyomavirus-
mediated alteration of the host system is the inactivation of the⁎ Corresponding author. Fax: +1 215 204 0679.
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doi:10.1016/j.virol.2008.02.020cellular protein phosphatase 2A (PP2A) by SV40 Sm t-Ag
(Sontag et al., 1993). PP2A targets a variety of viral (Prives,
1990) and cellular proteins (Arroyo and Hahn, 2005; Garcia et
al., 2000; Howe et al., 1998; Lin et al., 2006; Sontag et al., 1997;
Ugi et al., 2002); and plays critical roles in their regulation.
PP2A is an abundant serine/threonine-specific protein phospha-
tase in mammalian cells and is critical for many biological
processes, including development, differentiation and growth
control (Janssens and Goris, 2001). This enzyme exists as a
complex composed of a core and a variable unit. The core
enzyme consists of a catalytic C subunit (~36 kDa) and a regu-
latory A subunit (~65 kDa). The variable unit exists as different
465I.K. Sariyer et al. / Virology 375 (2008) 464–479isoforms but generally fall into three families designated B, B′
and B″ (Kremmer et al., 1997). This large number of variable
subunits allows the formation of numerous, but functionally
distinct, substrate-specific isoforms of PP2A. SV40 Sm t-Ag has
been reported to replace the B subunit in the PP2A complex and
may thereby modify the function of the enzyme complex (Hahn
et al., 2002).
JCV is a small human polyomavirus and is the etiological
agent of a fatal demyelinating disease, progressive multifocal
leukoencephalopathy (PML) (Berger and Concha, 1995; Raj and
Khalili, 1995; Safak et al., 2005). It shows a high degree of
sequence homology to the human BK virus (BKV) and the
rhesus macaque simian virus-40 (SV40) polyomaviruses in
coding regions (~70%), however, the non-coding regulatory
region of each virus is highly divergent between these viruses.
This divergence of the non-coding region plays a critical role in
the unique pattern of gene expression of each virus in different
cell types and tissues (Frisque andWhite, 1992; Major and Ault,
1995).
The late coding region of JCV encodes a small and highly
basic regulatory protein, agnoprotein, whose functions in the
JCV infection cycle are beginning to be investigated. Recent
findings suggest that it may play an important role in the JCV
replication cycle (Sariyer et al., 2006). In this regard, analysis of
phosphorylation site mutants, where Ser7, Ser11 and Thr21 were
mutated into Ala, showed that mutant viruses were unable to
continue the viral replication cycle (Sariyer et al., 2006). In
addition, we have previously demonstrated that agnoprotein
associates with JCV large T antigen (LT-Ag) and the cellular
transcription factor YB-1 and negatively affect their role in JCV
transcription (Safak et al., 2001, 2002). We have also analyzed
the effect of agnoprotein on cell cycle progression and found that
cells stably expressing agnoprotein largely accumulate at the G2/
M phase of the cell cycle (Darbinyan et al., 2002). Moreover, it
was recently reported that agnoprotein interacts with the cellular
proteins FEZ1 and HP1α and may promote the transport of
virions from the nucleus to the cytoplasm (Suzuki et al., 2005)
and thereby facilitates the propagation of JCV (Okada et al.,
2005).
The JCVearly coding region encodes the regulatory proteins,
LT-Ag and Sm t-Ag (Frisque et al., 1984) and several spliced
variants of the early proteins, called T's (Frisque, 2001; Frisque
et al., 2003). LT-Ag is known to play critical roles in both viral
DNA replication (Lynch and Frisque, 1990, 1991; Lynch et al.,
1994; Tavis and Frisque, 1991) and viral gene transcription
(Khalili et al., 1987; Lashgari et al., 1989; Tyagarajan and
Frisque, 2006). This protein was also shown to have an onco-
genic potential and its expression can lead to the induction of
tumors of neuronal origin in experimental animals (Krynska
et al., 1999; Small et al., 1986; Varakis et al., 1978). T′ proteins
were recently found to differentially interact with the retino-
blastoma family of tumor suppressor proteins (Frisque et al.,
2006; Trowbridge and Frisque, 1995; Tyagarajan and Frisque,
2006). Although the function of JCV Sm t-Ag in JCV regulation
and cellular transformation is unknown, functional studies with
SV40 Sm t-Ag showed an important role in permissive and
nonpermissive infections. Sm t-Ag enhances the ability of SV40LT-Ag to transform cells (Chen and Hahn, 2003; Gaillard et al.,
2001; Nunbhakdi-Craig et al., 2003; Porras et al., 1996, 1999;
Zhao et al., 2003). It is also believed that Sm t-Ag antagonizes
LT-Ag-induced cellular apoptosis and thereby contributes to
more efficient transformation of rat embryo fibroblasts (Kolzau
et al., 1999). In addition, transgenic animals created with a Sm t-
Ag deletion mutant of SV40 genome developed tumors almost
exclusively in highly mitotic tissues such as lymphoid organs
(Carbone et al., 1989; Choi et al., 1988) suggesting that Sm t-Ag
may play a significant role in tumor induction in nonproliferative
tissues. The tumorigenic potential of Sm t-Ag was linked to the
inhibition of PP2A by this protein (Ali and DeCaprio, 2001;
Rundell and Parakati, 2001; Sontag et al., 1993). Recent reports
also indicate that Sm t-Ag may function as a transfer factor to
specify PP2A targeting in cells and thereby modulate the tran-
scriptional activity of cellular genes including the androgen
receptor (Yang et al., 2005).
In this communication, we have investigated the regulatory
role of PP2A on agnoprotein dephosphorylation as well as the
effect of Sm t-Ag on this process. We provide evidence that
agnoprotein is targeted by PP2A for dephosphorylation and this
process can be inhibited by Sm t-Ag, suggesting the presence of
interplay between these three proteins.
Results
Agnoprotein coimmunoprecipitates with PP2A subunits
We have recently demonstrated that JCV agnoprotein is
phosphorylated by PKC and that phosphorylation site mutants
are unable to continue the viral replication cycle (Sariyer et al.,
2006). Since most phosphorylated proteins are subjected to
regulation by phosphatases (Arroyo and Hahn, 2005; Boutros
et al., 2007; Gallego et al., 2006; Gallego and Virshup, 2005,
2007; Jakubiec and Jupin, 2007; Jakubiec et al., 2006; Miller
et al., 1982; Wang and Liu, 2007) we sought to investigate
whether the phosphatase, PP2A (Heriche et al., 1997; Zhou et
al., 2003) targets JCVagnoprotein. To test this possibility, SVG-
A cells were transfected/infected with JCV Mad-1 strain and
whole cell extracts were prepared. Extracts were subsequently
examined for the presence of an agnoprotein:PP2A complex by
immunoprecipitation followed byWestern blotting. As shown in
Fig. 1A, the immunocomplexes obtained upon incubation of the
protein extracts with α-PP2A C antibody contained agnoprotein
(lane 6), while those immunoprecipitated with pre-immune sera
(control) did not (lane 4), which indicates the specificity of the
coimmunoprecipitation. In parallel, we also investigated
whether agnoprotein coprecipitates with both A and B subunits
of PP2A (Fig. 1B). Results showed that in fact it does but the
level of band intensity for agnoprotein resulting from copreci-
pitation with both anti-A and anti-B antibodies of PP2A is not as
strong as for that of C subunit case (compare lane 4 to 5 and 6
respectively).
To further investigate the interaction between PP2A and
agnoprotein, in vitro GST pull-down experiments were
performed. Whole cell extracts were prepared from glial cells
(U-87MG), which endogenously express a high level of PP2A,
Fig. 1. Agnoprotein interacts with PP2A. (A) Coimmunoprecipitation of
agnoprotein with PP2A C subunit. Whole cell extracts (500 μg) were prepared
from SVG-A cells [uninfected (−) or infected with JCVMad-1] at the indicated
days (d) post infection, subjected to immunoprecipitation (IP) using α-pre or
α-PP2A C antibody (2 μg) as indicated. Immunocomplexes were then ana-
lyzed by Western blotting using α-agnoprotein antibody as described in
Materials and methods. In lane 1, whole cell extract from SVG-A cells (20 μg)
was loaded as a positive control for agnoprotein. IgG-labeled arrow points the
light chain of the antibodies that were used for IP and detected by the sec-
ondary antibody. Ifxn denotes infection. (B) In parallel to the immunopreci-
pitation studies described in panel B, protein complexes were also precipitated
(IP) with antibodies that are directed against A (α-PP2A A rabbit polyclonal,
B (α-PP2A B mouse monoclonal) and C (α-PP2A C rabbit polyclonal)
subunits of PP2A or either with normal mouse serum (α-pre M) or normal
rabbit serum (α-pre R) as indicated using whole cell extracts from SVG-A cells
prepared at 14 days post infection. Immunocomplexes were then analyzed by
Western blotting using an anti-agno rabbit antibody. (C) GST pulldown assay.
Whole cell extracts prepared from SVG-A cells were incubated either with
GST or GST–Agnoprotein (Agno) (2 μg each), immobilized on GST–
Sepharose beads. Columns were extensively washed with binding buffer
and retained proteins were analyzed by Western blotting using α-PP2A C
antibody as described in Materials and methods. In lane 1, whole cell extract
from SVG-A cells (20 μg) was loaded as a positive control. (D) SDS-PAGE
analysis of GST and GST–agnoprotein followed by coomassie staining.
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fusion proteins immobilized on glutathione–Sepharose beads.
After washing, proteins retained on the columns were analyzedby immunoblotting using an antibody raised against agnopro-
tein. As shown in Fig. 1C, incubation of whole cell extracts with
Sepharose columns containing GST or GST–Agno resulted in
the specific retention of PP2A on a column that contains GST–
Agno (lane 3) but not on a column that contains GST alone
(lane 2). Fig. 1D illustrates the Coomassie blue-stained SDS-
PAGE gel of the full-length agnoprotein fused to GST, which
was used in this study. Of note, GST–agnoprotein is not
produced as a single band in bacteria as previously reported
(Safak et al., 2001). Altogether, results from in vivo and in vitro
protein–protein interaction studies strongly suggest that
agnoprotein and PP2A interact and form heterocomplexes.
Eighteen to thirty-six amino acid region of agnoprotein
interacts with PP2A
In the next series of experiments, we mapped the region of
agnoprotein which interacts with PP2A. A series of bacterially
expressed agnoprotein deletion mutants fused to GST were
incubated with protein extracts from glial cells (U-87MG) as
described in Materials and methods. After washing the columns,
protein complexes were resolved by SDS-PAGE and analyzed
byWestern blotting using an anti-PP2AC antibody. As shown in
Fig. 2A, removal of the regions of agnoprotein positioned
between residues 1 and 36 (lane 7); and 1 and 54 (lane 8) com-
pletely inhibited association of agnoprotein with PP2A. We ob-
served a reduced binding activity of a clone, which retains the
residues 1–54 (lane 4) compared to WT (lane 3). In addition, a
deletion mutant that retained the residues 1–36 showed a
comparably high level of binding activity to PP2A (lane 5).
Furthermore, two deletion mutants that contained residues 18 to
36 (lane 6 and 9) showed slightly higher binding efficiency
compared to WT (lane 3), which indicates that the residues
located between amino acid 18 to 36 of agnoprotein are critical
for binding to PP2A. Fig. 2B illustrates the Coomassie blue-
stained SDS-PAGE gel analysis of the full-length and mutant
agnoproteins, which were used in the GST pull-down assay. A
schematic of the GST pull-down assay depicting the regions of
agnoprotein, which bind to PP2A is presented in Fig. 2C.
Agnoprotein is dephosphorylated by PP2A
Above, we showed that PP2A targets JCV agnoprotein. In
addition, our recent studies demonstrated that agnoprotein is a
substrate for PKC (Sariyer et al., 2006). Since PP2A is known to
be a serine/threonine phosphatase, we next determined whether
PP2A could dephosphorylate PKC-phosphorylated agnopro-
tein. Agnoprotein was then produced as a fusion protein (GST–
Agno) in bacteria, purified to its homogeneity and phosphory-
lated by PKC (Sariyer et al., 2006). Dephosphorylation assay
was carried out using PP2A enzyme obtained from two different
sources, commercially available and immunoprecipitated one.
However, before addressing this question, we first determined
the activity of commercially available pure PP2A towards its
substrate. As shown in Fig. 3A, pure PP2A enzyme is active and
successfully dephospharylates its substrate (compare lane 1 to
lane 2). We then carried out PP2A-mediated dephosphorylation
Fig. 3. PP2A dephosphorylates agnoprotein. (A) Enzymatic activity of purified
PP2A on authentic substrate was measured according to manufacturer's
recommendations (Upstate) and expressed as relative activity compared to
without enzyme in the reaction. (B) Time course activity of PP2A on
phosphorylated agnoprotein. PKC-phosphorylated GST–agnoprotein was
equally distributed into reaction tubes, subjected to dephosphorylation by
purified PP2A at different time points and analyzed by autoradiography. Okadaic
acid was used as a specific inhibitor of PP2A in the reaction (lane 7). (C) PKC-
phosphorylated GST–agnoprotein was also subjected to dephosphorylation by
immunoprecipitated-PP2A and analyzed by autoradiography as described in
Materials and methods. PP2A was immunoprecipitated (IP) from whole cell
extracts prepared from SVG-A cells (500 μg) using either α-pre (2 μg) or α-
PP2A C antibody (2 μg) prior to dephosphorylation reaction. Immunoprecipi-
tated PP2A was split into 4 equal portions. One (+) or three (+++) portions of
immunoprecipitated PP2A were used in the reactions as indicated. In lane 6,
okadaic acid (Okad. Acid) was used to inhibit the dephosphorylation reaction.
Fig. 2. Eighteen to thirty-six amino acid region of agnoprotein is critical for
interaction with PP2A. (A) Bacterially produced GST or GST–agno fusion
protein or agnoprotein deletion mutants that were fused to GST were immo-
bilized on GST–Sepharose beads (2 μg each) and incubated with whole cell
extracts (300 μg) prepared from SVG-A cells overnight at 4 ° by racking.
Unbound proteins were washed and bound proteins were analyzed by Western
blotting using α-PP2A C antibody. In lane 1, whole cell extract was directly
loaded on the gel as a positive control (20 μg). (B) SDS-PAGE analysis of GST,
GST–Agno full-length and GST–Agno deletion mutants. Position of the GST–
Agno full length was indicated by an arrow. (C) Summary of the results obtained
from in vitro mapping assays. The relative binding activity of agnoprotein
and its deletion mutants is represented by + or − signs. +++, very strong binding;
++, strong binding; +, binding; and −, no binding.
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enzyme or using the one that is immunoprecipitated from whole
cell extracts, prepared from U-87MG cells. As demonstrated in
Fig. 3B, commercially obtained pure PP2A successfully
dephosphorylates agnoprotein in a time course study (compare
lane 1 to lanes 2–6) so does an immunoprecipitated PP2A
(Fig. 3C, lanes 2 and 3). However, the complexes that were
coimmunoprecipitated with pre-immune serum did not have a
significant effect on the level of agnoprotein dephosphorylation
(lanes 4 and 5), suggesting that dephosphorylation of agno-
protein by PP2A is specific. In order to further demonstrate the
specificity of the PP2A-mediated dephosphorylation of agno-
protein, a PP2A-specific inhibitor, okadaic acid, was included in
the reaction. In the presence of this inhibitor, we observed a
complete inhibition of the PP2A-mediated dephosphorylation
of agnoprotein (lane 6). Taken together, these studies demon-strate that PP2A specifically dephosphorylates PKC-phos-
phorylated agnoprotein.
Sm t-Ag associates with PP2A
JCV Sm t-Ag shows about 70% sequence identity at the amino
acid level to its counterpart SV40 Sm t-Ag. SV40 Sm t-Ag was
previously shown to inhibit the regulatory function of PP2A
(Sontag et al., 1993). To determine whether JCV Sm t-Ag might
468 I.K. Sariyer et al. / Virology 375 (2008) 464–479also interact with cellular PP2A, we performed in vitro GST pull-
down experiments. Bacterially expressedGSTor full-length Sm t-
Ag fused to GST was immobilized on glutathione–Sepharose
beads and incubated with whole cell extracts prepared from U-
87MG cells. After washing the beads with incubation buffer,
bound proteins were resolved by SDS-10% PAGE and analyzed
by Western blotting using an anti-PP2A C antibody. As
demonstrated in Fig. 4A, PP2A was retained on the Sepharose
column containing GST–Sm t-Ag full length (lane 3) but an
interaction of this type between PP2A and GST alone was not
observed (lane 2), indicating the specificity of association
between Sm t-Ag and PP2A. In addition, we identified the
protein domains within Sm t-Ag, which confers the interaction
with PP2A using a series of Sm t-Ag deletion mutants fused with
GSTwhich were prepared and incubated with whole cell extracts
prepared from U-87MG cells. A Sm t-Ag carboxy-terminal
deletion mutant retaining residues 1 to 124 showed a strong
binding activity (lane 4) but less than full-length (lane 3). AnotherFig. 4. The PP2A interaction domain of the Sm t-Ag localizes to its middle portion. (A)
immobilized on glutathione-S-transferase (GST) beads.Whole cell lysates prepared from
2 h. The columns were extensively washed with binding buffer as described inMaterials
PAGE and analyzed by Western blotting with an antibody directed against PP2A. (B) A
PAGE. (C) Schematic representation of Sm t-Ag and its deletionmutants. The relative bin
very strong binding; ++, strong binding; +, binding; +/−, weak binding and −, no bindicarboxy-terminal deletion mutant retaining residues 1 to 81,
however, lost its binding activity to PP2A (lane 5). Removal of the
amino-terminal region of Sm t-Ag positioned between residues 1
to 81 did not severely affect its interaction with PP2A (lane 6, aa
82–172). The magnitude of interaction of this clone with PP2A
appears to be closer to that was observed for full-length (compare
lane 6 with lane 3). As the deletion of the residues between 1 to
124 severely affected the ability of Sm t-Ag to interact with PP2A
(lane 7), retaining the residues between 82 to 124 showed strong
binding activity to PP2A (lane 8) indicating that the core
interaction domain of Sm t-Ag with PP2A is located between
residues 82 to 124 toward the central portion of the protein.
Late agnoprotein interacts with early protein Sm t-Ag
Our previous studies have shown that agnoprotein can
physically and functionally interact with the JCV early regu-
latory protein, LT-Ag. We have now analyzed if agnoprotein canSm t-Ag and its deletion mutants were expressed in bacteria as fusion proteins and
U-87MG cells were incubated with either GST–Sm t-Ag or its deletion mutants for
and methods and the proteins retained in the columnwere fractionated by SDS-10%
nalysis of GST, GST–Sm t-Ag and the deletion mutants of Sm t-Ag by SDS-12%
ding activity of Sm t-Ag and its deletionmutants is represented by + or− signs. +++,
ng.
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coimmunoprecipitation and GST pull-down assays. Whole cell
extracts were prepared from SVG-A cells infected or uninfected
with JCV Mad-1 strain as described in Materials and methods,
and incubated with either pre-immune serum (control) or anti-
Sm t-Ag antibody. Immunocomplexes were analyzed by
Western blotting for agnoprotein. As shown in Fig. 5A, immu-
nocomplexes obtained upon incubation of the protein extracts
with an anti-Sm t-Ag antibody contained agnoprotein (lane 5).
However, we did not detect agnoprotein immunoprecipitated
with the control pre-immune serum (lane 4), which indicates
specificity.
To investigate further the interaction between agnoprotein
and Sm t-Ag in vitro, GST pull-down experiments were per-
formed. As shown in Fig. 5B, incubation of Sepharose columns
containing GSTor GST–Agno with whole cell extracts prepared
from SVG-A cell infected with JCV Mad-1 resulted in the
specific retention of agnoprotein on the column containingFig. 5. The C-terminal portion of Sm t-Ag is important for agnoprotein interaction. (A
prepared from SVG-A cells infected (Ifxn) or uninfected with JCVMad-1 were subje
analyzed by Western blotting using α-agno antibody. In lane 1, whole cell extracts
Whole cell extracts, prepared from SVG-A cells, infected with JCVMad-1 were incub
beads. Bound proteins were analyzed byWestern blotting using an α-agno antibody a
loaded as a positive (+) control. In lane 2, whole cell extract (20 μg) from uninfected c
of Sm t-Ag maps to the C-terminal portion of the protein. GST pulldown assay was
mapping assays as described for Fig. 4C.GST–Sm t-Ag (lane 4) but not on that containing GST alone
(lane 3). Of note, no retention of agnoprotein by GST column
alone indicates the specificity of the interaction between agno-
protein and Sm t-Ag. Next, wemapped the interaction domain(s)
of Sm t-Ag with agnoprotein performing GST pull-down assays
using deletion mutants of Sm t-Ag (Fig. 5C). The C-terminal
region of the protein containing residues 82–172 is critical for
the interaction between Sm t-Ag and agnoprotein (lane 5). In
addition, a similar binding activity of 82–124 and 125–172
regions suggested that C-terminal region of Sm t-Ag may con-
tain more than one region responsible for interaction of agno-
protein with Sm t-Ag.
Sm t-Ag inhibits PP2A-mediated dephosphorylation of agnoprotein
Previous studies have shown that Sm t-Ag of SV40 interacts
with the regulatory A subunit of PP2A and this interaction
results in the replacement of regulatory B subunit. Since PKC-) Agnoprotein coimmunoprecipitates with Sm t-Ag. Whole cell extracts (500 μg)
cted to immunoprecipitation (IP) using α-pre rabbit and α-Sm t-Ag antibody and
from infected cells were loaded as a positive control. (B) GST pulldown assay.
ated with either GSTor GST–Sm t-Ag, immobilized on Glutathione–Sepharose
s described for Fig. 2. In lane 1, whole cell extract (20 μg) from infected cells was
ells was loaded as a negative (−) control. (C) The agnoprotein interaction domain
carried out as described for panel B. (D) Summary of the results from in vitro
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C), we reasoned that JCV Sm t-Ag may inhibit PP2A-mediated
dephosphorylation of agnoprotein. In order to investigate this
possibility, we performed in vitro inhibition studies. Agnopro-
tein was produced in bacteria as a fusion protein (GST–Agno),
purified and phosphorylated by PKC (Sariyer et al., 2006). PP2A
was immunoprecipitated from whole cell extracts (U-87MG
cells) using anti-PP2A C antibody and was used as a dephos-
phorylation enzyme in the reaction. As shown in Fig. 6A, PKC-
phosphorylated agnoprotein was incubated either with increas-
ing concentration of GST–Sm t-Ag (lanes 7–9) or GST (lanes
10–12) and results showed that PP2A dephosphorylated
agnoprotein (lane 6) in a similar extent as was observed for
Fig. 3C. However, addition of Sm t-Ag to the dephosphorylation
reaction significantly inhibited the PP2A-mediated dephosphor-
ylation of agnoprotein (lanes 7–9) compared to the control (lane
6). Under identical reaction conditions, addition of GST protein
did not alter significantly the ability of PP2A to dephosphorylate
agnoprotein (lanes 10–12). Alkaline phosphatase (AP) was,Fig. 6. Sm t-Ag inhibits agnoprotein dephosphorylation by PP2A. (B) Full-length ag
purified its homogeneity and phosphorylated by PKC as described previously
dephosphorylation by PP2A, fractionated on SDS-PAGE and analyzed by autoradio
(AP) was used as a control to dephosphorylate agnoprotein (Sadowska et al., 2003).
respectively) was added to the reaction. Similarly, in lanes 7–9, GST–Sm t-Ag was
lane 10–12, an increasing amount of GST (0.5, 1.0 and 1.5 μg/lane respectively)
positive control. (B) JCV Sm t-Ag inhibits PP2A activity. Inhibition reaction is des
expressed in bacteria and purified to their homogeneity. Both proteins were added in
amount of phosphate released from substrate was colorimetrically determined at 600
in percent.however, used as a negative control in the reaction to remove the
phosphate groups from agnoprotein (lane 2) as previously de-
monstrated (Sadowska et al., 2003). Additionally, addition of
GST Sm t-Ag into the AP reaction in increasing amounts did not
have an effect (lanes 3–5) on the reaction, further suggesting that
inhibition of PP2A by Sm t-Ag is specific. Taken together, our
in vitro dephosphorylation studies showed that Sm t-Ag has
the ability to inhibit the PP2A-mediated dephosphorylation of
agnoprotein.
Moreover, we addressed the question whether Sm t-Ag
directly inhibits PP2A activity or Sm t-Ag binds to agnoprotein
and obscures the substrate availability, leading to indirect
inhibition of PP2A activity. Two differentiate between these
two possibilities; we purchased a PP2A phosphatase kit from
Upstate, which contains pure PP2A and an authentic substrate for
PP2A; and performed phosphatase assay in the presence of either
increasing amounts of GST–Sm t-Ag (Fig. 6B, lanes 3–5) or that
of GST (Fig. 6B, lanes 6–8). Our results show that Sm t-Ag
significantly inhibited PP2A activity when directly added to thenoprotein was expressed in bacteria as a GST fusion protein (GST–Agno) and
(Sariyer et al., 2006). PKC-phosphorylated agnoprotein was subjected to
graphy as described in Materials and methods. In lane 2, alkaline phosphatase
In lanes 3–5, an increasing amount of GST–Sm t-Ag (0.5, 1.0 and 1.5 μg/lane
also added into the reaction in increasing amount as described for lanes 3–5. In
alone was used. In lane 1, phosphorylated GST–agnoprotein was loaded as a
cribed in Materials and methods in detail. Briefly, GST and GST Sm t-Ag was
to reaction in increasing amounts (0.5. 1.0 and 1.5 μg/lane) as indicated and the
nm wavelengths. The enzyme activity was expressed in “relative PP2A activity”
Fig. 7. Viral replication and gene expression were substantially down-regulated in the absence of full-length Sm t-Ag expression. (A) Amino acid alignment of JCV Sm
t-Ag and SV40 Sm t-Ag. (B) Schematic comparison of SV40 Sm t-Ag regions with that of JCV Sm t-Ag. The position of J domains, PP2A binding domains and cystein
clusters are indicated. (C) Schematic representation of JCVMad-1 early coding region, where Ser90 (TCT) of Sm t-Ag was converted into a stop codon as described in
Materials and methods. Numbering is according to JCV Mad-1 strain (GenBank # NC_001699, formerly J02226). (D) Dpn I assay. Primary human fetal glial cells
(PHFG) (4 million cells/75 cm2 flask) were transfected/infected either withWT (5 μg) or Mut genome (5 μg) by lipofectin method. At 7d, 14d and 21d posttransfection,
low molecular weight DNAwas isolated (Ziegler et al., 2004) and analyzed by Dpn I assay (Hirt, 1976). (E) In parallel, either nuclear or cytoplasmic extracts were
prepared from transfectants and analyzed byWestern blotting using anti-LT-Ag (PAb-2000), anti-VP-1 (PAB597, a gift fromDr.W. Atwood), anti-agnoprotein and anti-
Sm t-Ag antibodies as indicated.
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6–7) suggesting that Sm t-Ag exhibits the ability, at least in part,
to directly inhibit PP2A in vitro.
C-terminal portion of Sm t-Ag is critical for its function
The N-terminal 82-amino acid region of Sm t-Ag is shared
with LT-Ag. Therefore, any unique function associated with Sm t-
Ag most likely lies within its unique C-terminal region. Com-
parison of JCV and SV40 Sm t-Ags at the amino acid level
indicates that both proteins exhibit closer to 70% homology
although more divergent sequences are clustered in the middle
portion of the each molecule (Fig. 7A). Functional domains such
as J domain, PP2A binding domain and cystein clusters are po-sitioned relatively similar locations within each protein (Fig. 7B).
Moreover, our results demonstrated that the C-terminal region of
Sm t-Ag is critical for interaction with both agnoprotein (Fig. 5C)
and PP2A (Fig. 4A). To understand the role of Sm t-Ag in JCV
regulation, we introduced a stop codon at amino acid Ser90
immediately after splice donor site of the gene so that the unique
C-terminal portion of the protein was not produced. We then
evaluated the impact of this stop codon on viral replication and
gene regulation. For this purpose, primary human fetal glial cells
(PHFG) were either transfected/infected with JCV Mad-1 WT
strain or JCV Mad-1 Sm t-Ag mutant genome. Low molecular
weight DNA was then isolated at indicated time points and
analyzed by Dpn I digestion and Southern blotting. As shown in
Fig. 7D, the replication efficiency of WT genome increased
substantially by 21d posttransfection (lanes 2–4), but that of Mut
was significantly inhibited (lanes 5–7), suggesting that the unique
C-terminal region of Sm t-Ag plays a critical role in JCV
replication. In parallel, we also analyzed the expression level of
LT-Ag, VP-1 and agnoprotein from both WT and mutant back-
grounds by Western blotting. We obtained consistent results as
observed for the replication studies (Fig. 7D) in that the expres-
sion level of LT-Ag, VP-1 and agnoprotein from Mut virus
is significantly reduced compared toWT (Fig. 7E, compare lanes
2–4 to 5–7 in respective panels). In Fig. 7E, bottom panel, the
absence of Sm t-Ag expression was demonstrated in cells that
were transfected/infected with mutant virus genome. In addition,
we also subcloned the early coding region of WT and mutant
separately into an expression vector to demonstrate the efficient
splicing of the early transcripts regardless of the presence of the
stop codon in the genome. Our results showed that the expression
level of LT-Ag for both WT and mutant genomes was relatively
equal by Western blotting (data not shown), suggesting that theFig. 8. Effect of PP2A inhibition on JCV replication and gene expression.
(A) Inhibition of PP2A negatively affects JCV replication. SVG-A cells. 2×105
cells per 35-mm tissue culture dish were transfected/infected with JCV genome
(2 μg/plate) in the presence and absence of 50 pmol of non-targeting siRNA or
Smartpool PP2AC siRNA (PP2AC siRNA, Dharmacon, Lafayette, CO). At the
48 h post infection, cells were trypsinized and split into two equal portions. One
half of the samples were used to prepare low molecular weight DNA for Dpn I
assay and the other portion was used to prepare whole cell extracts for Western
blotting. DNA was digested with both Bam HI and Dpn I and analyzed by
Southern blotting using labeled JCV genomic DNA as probe. Dpn I enzyme
digests only transfected (input) DNAand leaves intact the newly replicatedDNA.
In lane 1, plasmid containing the Mad-1 genome was digested with Bam HI only
and 0.1 ng of it was run on the gel as a positive control. In lane 2, the DNA sample
from untransfected/uninfected cells were processed as in lanes 3–5 and was
loaded as a negative control. The arrow points to the replicated DNA and
the bracket indicates the input DNA. Tfxn/Inf denotes transfection/infection,
i.e., introduction of the Mad-1 JCV genome into cells by transfection.
(B) Quantitative representation of the results from panel A. The bands
corresponding to the replicated DNA was quantitated in each lane (lanes 3–5)
by densitometry and normalized relative to the band intensity on lane 3. The
standard deviations of the data are presented as error bars (C) Western blot
analysis of the whole cell extracts prepared in parallel to the replication assay in
panel A, using specific antibodies against agnoprotein, PP2AC and Grb2. In lane
1, sample from untransfected/uninfected cells was loaded as a negative control.
The small bracket denotes the non-specific bands that indicate the equal protein
loading for agnoprotein. Grb2 was probed as a loading control for PP2AC.
Fig. 9. Agnoprotein triple phosphorylation mutant is resistant to a mutation in Sm t-Ag. (A) Schematic representation of a double mutant of JCVMad-1 strain on Sm t-
Ag and agnoprotein. On agnoprotein, Ser7, Ser11 and Thr21 were converted into Ala. On Sm t-Ag, Ser90 was converted into a stop codon. (B). Analysis of the growth
properties of JCV WT Mad-1 and double mutant by Dpn I assay. SVG-A cells (5 million cells/75 cm2 flask) were transfected/infected either with WT (5 μg) or Mut
genome (5 μg) by lipofectin method. At 5d, 10d and 15d posttransfection, low molecular weight DNAwas isolated (Ziegler et al., 2004) and analyzed by Dpn I assay
(Hirt, 1976). (C) In parallel, cytoplasmic extracts were prepared from transfectants and analyzed by Western blotting using anti-agnoprotein antibody.
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due to an inefficient splicing of early transcripts of the mutant, but
rather due to the lack of expression of the C-terminal region of Sm
t-Ag. These results suggest that the unique region of Sm t-Ag
plays an important role in the JCV replication cycle.
Effect of PP2A inhibition on JCV replication
Next, we investigated the effect of PP2A inhibition on JCV
replication by RNA interference. SVG-A cells were transfected/
infected with JCV genome in the presence and absence of a non-
specific siRNA or siRNA specific for PP2A. Two days post-
transfection, the replication efficiency of the samples was
determined by Dpn I assay. Results showed that the replication
of the JCV genome was significantly inhibited (approximately
5-fold, Figs. 8A and B, lane 5) compared to untreated samples(lane 3) or samples, which were treated with non-specific siRNA
(lane 4) suggesting that PP2A plays an important role in JCV
replication cycle. This reduced replication in siRNA-treated
samples (lane 5) cannot be simply attributed to the inefficient
transfection efficiency of JCV genome into the cells, because the
level of input DNA in three experimental groups appears to be
equal (compare lane 3 to 4 and 5). In addition, since we did not
observe a significant level of difference between untreated and
treated samples with respect to input DNA levels, the observed
effect on JCV DNA replication appears to be mostly due to a
specific inhibition of PP2A by siRNA rather than a non-specific
toxicity of the treatment.
In parallel, the expression levels of both PP2A and agnoprotein
were also analyzed by Western blotting. The expression levels of
both proteins were considerably lower in samples treated with the
specific siRNA (Fig. 8C, lane 4) compared to either non-treated
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findings suggest that PP2A plays a critical role in the JCV re-
plication cycle.
Effect of a double mutation on Sm t-Ag and agnoprotein on
viral replication cycle
Our results demonstrate that Sm t-Ag may influence the level
of agnoprotein dephosphorylation through the inhibition of
PP2A. We then reason that a triple phosphorylation mutant of
agnoprotein should be resistant to mutations in Sm t-Ag. To
address this question, we have created a double mutant of JCV
Mad-1 strain on Sm t-Ag and agnoprotein as described in
Materials and methods, and analyzed the impact of these
mutations on the replication properties of JCV by Dpn I assay.
WTand mutant genomes were transfected into SVG-A cells and
low molecular weight DNA was isolated at 5, 10 and 15 day
posttransfection and analyzed by Southern blotting. As shown in
Fig. 9C, the double mutant behaves very much like agnoprotein
triple phosphorylation mutant alone during the replication cycle
as previously reported (Sariyer et al., 2006). That is, this double
mutant is also unable to continue to its replication after first
round of infection cycle (compare lanes 2–4 with 5–7). These
findings confirms our assumption that agnoprotein might be an
important target of Sm t-Ag with respect to the regulation of its
dephosphorylation, and therefore it appears that the triple
phosphorylation mutant of agnoprotein is resistant to a mutation
on Sm t-Ag.
Discussion
The function of regulatory proteins is often modulated by
posttranslational modifications, including phosphorylation. This
modification is known to affect the activity of many target
molecules in a positive and negative manner depending on the
nature of the target. For instance, previous studies have shown
that the initiation of viral DNA replication is regulated by the
phosphorylation state of SV40 LT-Ag (Cegielska et al., 1994b;
Scheidtmann et al., 1991b), and PP2A is the primary
phosphatase, involved in this regulation. PP2A removes the
phosphate moieties from Ser120, Ser123 and Thr124 on SV40
LT-Ag and stimulates the origin unwinding activity of this
protein (Cegielska et al., 1994a,b; Cegielska and Virshup, 1993).
It is also possible that PP2A plays regulatory roles in the function
of agnoprotein through the regulation of the phosphorylation
state of this protein during the infection cycle.
We have recently showed that agnoprotein is subject to
phosphorylation by PKC and further analysis of agnoprotein
phosphorylation site mutants, showed that they are defective for
viral replication (Sariyer et al., 2006). Since agnoprotein is
phosphorylated by a serine/threonine kinase, PKC, we reasoned
that agnoprotein might be a substrate for the PP2A. In the present
study, we demonstrate that PP2A dephosphorylates agnoprotein
(Fig. 3B and C) and that the N-terminal half of agnoprotein, in
which the PKC phosphorylation sites are localized (Fig. 3D), is
critical for interaction with PP2A (Fig. 2A). It should be
mentioned here that the interaction observed between PP2A andagnoprotein could be both stoichiometric and enzymatic, be-
cause there are a number of cases reported in the literature
supporting this case. For instance, SV40 Sm t-Ag was reported
to have a stable interaction with PP2A and inhibits the activity of
this enzyme (Yang et al., 1991). Similarly, PP2A was also re-
ported to form a stable complex with Shc and regulates the
dephosphorylation of this protein (Ugi et al., 2002). As such, the
interaction that we observed between agnoprotein and PP2A
could be in both levels, stoichiometric and enzymatic.
In addition, we showed that Sm t-Ag interacts with the viral
late agnoprotein, through its C-terminal region (Fig. 5C). Addi-
tional mapping studies revealed that the interaction domain of
Sm t-Ag with agnoprotein and PP2A overlaps (Fig. 4A), sug-
gesting that agnoprotein and PP2A may compete with one
another for association with Sm t-Ag. The importance of inter-
actions among these three proteins was demonstrated by the
observation that Sm t-Ag inhibits agnoprotein dephosphoryla-
tion by PP2A (Fig. 6A), which may be an important regulatory
mechanism for JCV replication.
Since the interaction domain of Sm t-Ag with agnoprotein
and PP2A is located within its unique region, we analyzed the
effect of this region on the JCV life cycle by mutational analysis.
We introduced a stop codon at Ser90 (Fig. 7C) immediately after
the splice donor site of JCVearly genome so that the C-terminal
unique region of Sm t-Ag is not produced during the infection
cycle (Fig. 7E). Results showed that replication of JCV without
the unique region of Sm t-Ag is severely impaired (Fig. 7D).
This suggests that Sm t-Ag, although not directly involved in
JCV replication, appears to play an important role in JCV life
cycle, perhaps through interaction with agnoprotein and PP2A.
Similarly, we investigated the functional significance of PP2A in
JCVreplication cycle by siRNA targeting, and observed that that
inhibition of PP2A expression results in a considerable reduction
in viral replication (Fig. 8A), which also emphasizes the critical
role of PP2A in JCV life cycle. Mutational studies with SV40
Sm t-Ag supports our findings and such studies demonstrated
that Sm t-Ag significantly contributes to the viral replication
cycle (Cicala et al., 1994; Jog et al., 1990; Shenk et al., 1976;
Topp, 1980). In particular, studies conducted by Cicala et al
(Cicala et al., 1994) demonstrated that mutant virus that lacks the
Sm t-Ag replicates less efficiently than the wild-type virus. The
role of Sm t-Ag in viral DNA replication was even further
investigated by microinjection studies, where SV40 DNA was
injected into CV1 cells with and without purified Sm t-Ag and
was analyzed by Southern blotting. It was found that the
replication of either wild-type or Sm t-Ag deletion mutant
DNA increased three-to fivefold in cells coinjected with purified
Sm t-Ag, suggesting that SV40 Sm t-Ag has a stimulatory effect
on viral DNA replication in vivo.
Addition of a phosphate moiety to the target molecules is
catalyzed by specific kinases and removal of the same group is
carried out by specific phosphatases. As a result, there is a well-
balanced network of kinases and phosphatases in a cell and this
equilibrium is crucial for a cell to accurately respond to the
environmental cues. Outside invaders such as viruses shift this
balance toward one side by modifying the cell environment in
such a way that the host machinery is exploited by the virus for
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this work for JCV Sm t-Ag of SV40 was also previously shown
to target PP2A in host cells (Sontag et al., 1993, 1997).
Mapping and point mutation analysis of the interaction domain
of SV40 Sm t-Ag with PP2A revealed that central portion of the
protein, specifically residues including Cys97, Pro101 and
Cys103 are critical in this interaction (Mungre et al., 1994;
Porras et al., 1996; Sontag et al., 1993). These critical residues
are also located within the interaction domain of JCV Sm t-Ag
with PP2A. The functional significance of PP2A targeting by
SV40 Sm t-Ag is not fully understood for SV40 infection cycle.
However, it appears that at least in the absence of viral infection
cycle, this targeting may facilitate cell cycle progression and
therefore play a critical role in the onset of cell transformation
(Hahn et al., 2002).
Recent crystallography studies have shown that not only
does the unique region of SV40 Sm t-Ag interact with PP2A but
also the J domain (Cho et al., 2007). The previous biochemical
interaction studies between SV40 Sm t-Ag and PP2A appear to
be consistent with the these recent crystallographic findings,
because although the J domain is not essential for the interaction
between SV40 Sm t-Ag and PP2A, the deletion of this domain
significantly decreased the inhibitory activity of Sm t-Ag on the
PP2A core dimer (Mateer et al., 1998), suggesting that the J
domain enhances the binding of Sm t-Ag to the PP2A subunit.
Our binding studies (Fig. 4) is also consistent with the these
crystallographic and previous biochemical studies (Cho et al.,
2007; Mateer et al., 1998), in that although the core interaction
domain of JCV Sm t-Ag with PP2A is located within the unique
region of the protein, the J domain appears to significantly
contribute to this interaction, because the deletion of the first 81
amino acid region of JCV Sm t-Ag negatively affects this
interaction (Fig. 4A).
Our in vitro inhibition studies demonstrated that JCV Sm t-Ag
is able to inhibit PP2A-mediated agnoprotein dephosphorylation
(Fig. 6A). These results are similar to the previously reported
studies with SV40 Sm t-Ag. It was demonstrated that SV40 Sm t-
Ag can inhibit the PP2A-mediated dephosphorylation SV40 large
T antigen and cellular transcription factor, p53 (Scheidtmann
et al., 1991a,b) in vitro. In infection cases, however we think that a
partial inactivation of PP2A by Sm t-Ag is more likely, because a
total inactivation would lead to deleterious consequences, such as
an early cell death and therefore an abortive infection. A recent
report by Yang et al. (Yang et al., 2005) supports such a partial
inactivation case, which suggests that Sm t-Ag can orient PP2A
towards specific substrates rather than totally inhibiting its en-
zymatic activity.
In light of the data presented in this work with respect to
functional interactions among the three proteins, combined with
the previous analysis of agnoprotein phosphorylation mutants
(Sariyer et al., 2006), one can speculate that Sm t-Ag may
directly contribute to the maturation process of infectious viral
particles through the regulation of the timing of agnoprotein
dephosphorylation by PP2A. In other words, Sm t-Ag may
regulate the timing of the dephosphorylation of agnoprotein by
PP2A during the infection cycle. It is possible that during the
early phases of the infection cycle, Sm t-Ag may inhibit thedephosphorylation of agnoprotein by PP2A and may prevent
the process of the formation of immature capsids (i.e. empty
capsids). In fact, characterization of a double mutant of JCV
(Fig. 9B) suggested that in deed Sm t-Ag may be involved
in regulation of agnoprotein dephosphorylation, because this
double mutant behaves much like the triple phosphorylation
mutant of agnoprotein during the infection cycle. That is, this
mutant cannot continue its replication cycle as the case observed
for the triple phosphorylation mutant of agnoprotein, suggesting
that Sm t-Ag may in fact target agnoprotein for the regulation of
its phosphorylation during the infection cycle and therefore may
contribute the maturation of viral capsids. It is also possible that
the dephosphorylated form of agnoprotein is critical for the
efficient release of viral particles from infected cells toward the
late stages of the infection cycle. In this case, PP2A may regain
its full activity by being released from Sm t-Ag. Agnoprotein
may play a critical role in the release of PP2A from Sm t-Ag by
competing for the same binding site on Sm t-Ag. Our map-
ping studies support this possibility, since we showed that the
Sm t-Ag interaction domains for PP2A and agnoprotein overlap
(Figs. 4A and 5C).
Viruses have developed interesting strategies to deregulate
cells through PP2A. Cytomegalovirus (CMV), for example,
contains a cellular PP2A holoenzyme, which is probably in-
volved in the dephosphorylation of cellular proteins during the
early infection cycle (Michelson et al., 1996). DNA tumor
viruses, including adenoviruses and polyomaviruses also encode
proteins that specifically target PP2A. E4orf4 from adenovirus
interacts with PP2A and down-regulates JunB transcription,
which may play a role in the viral infection cycle by regulating
the apoptotic response of the infected cells (Kleinberger and
Shenk, 1993). In this regard, it was found that the interaction of
E4orf4 with PP2A leads to the apoptosis of transformed cells
(Shtrichman and Kleinberger, 1998). Sm t-Ags of SV40 and
polyomavirus as well as polyomavirus middle Twere also found
to target PP2A (Cegielska et al., 1994a; Pallas et al., 1990;
Virshup et al., 1989, 1992), and this targeting appears to be
required for viral-induced transformation. It may also be impor-
tant for the viral replication cycle, perhaps through the mo-
dification of PP2A-dependent signaling pathways by viral
regulatory proteins in infected cells. Taken together, studies
with the regulatory functions of JCV proteins will provide new
insight into the mechanism of the regulatory pathways of JCV
infection cycle, which may in turn help us to develop effective
therapeutic strategies against PML.
Materials and methods
Cell culture
SVGA is a clonal population of a human glial cell line that
was established by transformation of fetal glial cell line with an
origin defective SV40 mutant and has been described
previously (Major et al., 1985). U-87MG (ATCC HTB14) is a
human glioblastoma cell line. Both SVGA and U87MG cell
lines were grown in Dulbecco's Modified Eagle's Medium
(DMEM) supplemented with 10% heat-inactivated fetal bovine
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ml). They were maintained at 37 °C in a humidified atmosphere
with 7% CO2. Primary Human Fetal Glial (PHFG) cells were
prepared and maintained as previously described (Daniel and
Frisque, 1993; Swenson et al., 1996).
Plasmids
Sm t-Ag full-length and its deletion mutants were cloned into
a prokaryotic expression vector (pGEX2T) at Bam HI/Eco RI
site by a PCR amplification method using specific primers.
Forward primers were
Sm t-Ag 5′-Bam HI (5′-ACCTTCCAGGATCCATGGA-
CAAAGTGCTGAATAGGGAG-3′),
FP aa 82 (5′-ACCTTCCA GGATCCATGGTTGGTTGT-
GATTTTCCTCCTAAT-3′),
FP aa 125 (5′-ACCTTCAGGATCCATGTTTTTAAGAAG-
CAGCCCACTT-3′).
Reverse primers were
Sm t-Ag 3′-Eco RI (5′-ACCTCCAGAATTCTTAAAGCTT-
TAGATCCCTGTA -3′),
RP aa 124 (5′-ACCTCCAGAATTCTTATTTTCAGTTTC-
TATGCCTTAA-3′),
PR aa 81 (5′-ACCTCCAGAATTCCTCTGAACTATT-
CCATGTACCAAA-3)
The resulting PCR fragments were digested with Bam HI/
Eco RI and subcloned into the Bam HI/Eco RI sites of the
pGEX2T vector. GST–Agnoprotein (1–71) and deletion
mutants of agnoprotein fused to GST protein (1–54, 1–36,
18–37, 37–71, 55–71 and 18–54) were described previously
(Safak et al., 2001).
Site-directed mutagenesis
A stop codon was introduced into Sm t-Ag coding region
right after splice donor site converting Ser90 codon to a stop
(TAA) codon utilizing a ExSite-PCR based Kit (Stratagene).
The following primers were used in the PCR-mediated muta-
genesis as described previously (Akan et al., 2006; Sariyer et al.,
2006).
Primer 1. 5′-TCAGAGGTTGGT TGTGAT TAACCTCCT
AAT TCT GATACC C-3′ Primer 2. 5′-G GGTATC AGA ATT
AGG AGG TTA ATC ACA ACC AAC CTC TGA -3′. This
plasmid is called Bluescript KS Mad-1 Sm t-Ag Mut (Ser90 to
Stop). We also created a double mutant of JCV Mad-1 strain on
agnoprotein and Sm t-Ag as follows. Creation of a triple phos-
phorylation mutant of agnoprotein was previously described
(Sariyer et al., 2006) and the plasmid was called Bluescript KS
(BstXI−) Mad-1 Mut3(Agno Ser7, Ser11 and Thr21 to Ala). Sm
t-Ag mutant described above was also subloned into Bluscript
KS (BstXI−) background. By exchanging the BstXI/EcoNI
fragment on Sm t-Ag mutant with the same fragment form triple
phosphorylation mutant, we have created a double mutant ofJCV Mad-1 and called Bluescript (BstXI−) Sm t-Ag (Ser90 to
stop) +Mut3(Agno Ser7, Ser11 and Thr21 to Ala).
Immunoprecipitation and Western blotting
Five hundred micrograms of whole cell lysates were prepared
from SVG-A cells infected with JCV Mad-1 or from uninfected
cells in lysis buffer {25 mM Tris–HCl (pH 7.4), 150 mM NaCl,
10mMHEPES pH 7.0, 1 mMDTT, 10%Glycerol, 1 mMEDTA,
0.5 NP-40 and complete protease inhibitors (Sigma)}. Cell
lysates (0.5 mg) were incubated with either normal mouse or
rabbit serum (2 μg) or with an anti-PP2A C antibody directed
against the C (2 μg, Santa Cruz, Cat #: SC-14020) or the A
subunit (2 μg, Santa Cruz, Cat #: SC-15355) or the B (2 μg,
Upstate, Cat #: 05-592) subunit by rocking at 4 °C for 2 h.
Immunocomplexeswerewashed three timeswith lysis buffer and
analyzed by Western blotting using a polyclonal antibody raised
against agnoprotein (Safak et al., 2002). A reciprocal immuno-
precipitation andWestern blot analysis was also performed on the
same extracts to detect agnoprotein–Sm t-Ag interaction as de-
scribed above. Five hundred micrograms of whole cell extract
prepared from infected cells were immunoprecipitatedwith either
normal rabbit serum (2 μg) or rabbit polyclonal antibody raised
against the C-terminal unique region of Sm t-Ag (PAb 2081,
2 μg, we raised this antibody ourselves in rabbit) and immu-
nocomplexes were analyzed by Western blotting using poly-
clonal anti-agnoprotein antibody (Safak et al., 2002).
GST affinity chromatography assay (GST-pull down)
Expression and purification of GST and GST fusion proteins
were previously described (Safak et al., 1999a,b). Interaction of
agnoprotein with PP2A was tested by GST-pull down assay as
described previously (Safak et al., 2001, 2002). Twomicrograms
of either GST or GST–Agno immobilized on Sepharose beads
were incubated with whole cell extracts prepared from U-87MG
cells for 2 h at 4 °C in lysis buffer containing 50 mM Tris–HCl
(pH 7.4), 150 mMNaCl, and 0.5%Nonidet P-40. Columns were
then washed extensively with lysis buffer and retained protein
complexes were resolved by SDS-10% PAGE followed by
Western blot analysis using an anti-PP2AC antibody. Interaction
of Sm t-Ag with PP2A or that of agnoprotein was also tested as
described above.
In vitro kinase assay
Kinase assays were performed as previously described
(Sariyer et al., 2006). Briefly, GST and GST-agnoprotein full-
length (1–71) were expressed in bacteria and were purified as
described previously (Kim et al., 2003; Sadowska et al., 2003).
Onemicrogram of bacterially expressed GSTorGST-agnoprotein
(1–71) was incubated with 10 U of PKC (Promega) in kinase
reaction mixture containing 25 mM Tris–HCl (pH 7.4), 20 mM
MgCl2, 5 mMDTT, 2.5 µCi of [γ-
32P]-ATP, and 10% glycerol at
30 °C for 1 h. After the kinase reaction, phosphorylated proteins
were used for inhibition studies and were fractionated by SDS-
12% PAGE and visualized by autoradiography.
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The purified PP2A enzyme (Cat. #: 14-111), phosphatase assay
kit (Cat. #: 17-313) and a substrate for PP2A (K-R-pT-R-R, Cat. #:
12-219) were all purchased from Upstate Company. GST and
GST–Sm t-Ag proteins were expressed in bacteria and purified to
their homogeneity. The release of phosphate from the substrate by
PP2A was colorimetrically measured by Malachite green phos-
phatase assay according to the manufacturer's recommendations.
Either GST alone (control) or GST Sm t-Ag was added to the
reaction as described under the related figure legend and the
amount of the released phosphate was determined by extrapolating
the calorimetrically measured data points to the standard curves
according to the manufacturer's recommendations.
Inhibition of dephosphorylation assay
One microgram of bacterially expressed GST–agnoprotein
was phosphorylated by PKC as described above (see in vitro
kinase assay). The kinase reaction was stopped by addition of
1 µg of Protein Kinase C Inhibitor Peptide (Calbiochem, Cat. 05-
23-4904) into the reaction mixture. Phosphorylated GST–
agnoprotein was desphosphorylated both with purified and
immunoprecipitated PP2A. The purified PP2A enzyme, phos-
phatase assay kit (Cat. #: 17-313) and an authentic substrate for
PP2A (Cat. #: 12-219) were both purchased from Upstate.
Phosphorylated GST–agnoprotein was equally distributed into
reaction tubes. Immunoprecipitated PP2A was prepared from
whole cell extracts from SVGA cells (500 μg) using a mono-
clonal antibody against PP2A (3 μl, Upstate, Cat. 16-125D).
Immunocomplexes were washed three times with pNPP Ser/Thr
assay buffer (Upstate, Cat. 20-179) and was resuspended in the
same buffer. Immunoprecipitated PP2A (IP-PP2A) enzyme was
subsequently used for dephosphorylation assay as described in
the related figure legend. Normal serum was also used for
immunoprecipitation as a negative control above. In some re-
actions, a specific inhibitor of PP2A (okadaic acid, 2 ng/ml)
(Sigma, Cat. 1355544) was used to inhibit PP2A activity. All
reactions were performed in pNPP Ser/Thr assay buffer (50 µl) at
30 °C for various durations of time as indicated under related
figure legends. Dephosphorylated proteins were fractionated by
12% SDS-PAGE and visualized by autoradiography.
Whole cell and nuclear extract preparation
Whole cell and nuclear extracts were prepared as described
previously (Dignam et al., 1983; Sadowska et al., 2003; Safak
et al., 2002).
Targeting of PP2A by siRNA and JCV replication
The replication efficiency of JCV was assayed by employing
Dpn I assay as described previously (Akan et al., 2006; Sariyer
et al., 2006). SVG-A cells (2×105 cells per 35-mm tissue
culture dish) were transfected/infected with JCV genome (2 μg/
plate) in the presence and absence of 200 μmol of Smartpool
PP2Ac siRNA or non-targeting siRNA (NS siRNA, Dharma-con, Lafayette, CO). At the 48 h post infection, low molecular
weight DNA containing both input and replicated viral DNA
was isolated by Qiagen spin columns (Ziegler et al., 2004),
digested with Bam HI and Dpn I enzymes, resolved on 1%
agarose gel and analyzed by Southern blotting using labeled
probe prepared from whole Mad-1 genome (Ziegler et al.,
2004). Dpn I enzyme digests only transfected (input) DNA and
leaves replicated DNA intact.
In addition, to analyze the effect of Sm t-Ag stop mutant
on viral replication, primary human fetal glial cells (PHFG) (4
million cells/75 cm2 flask) were transfected/infected either with
WT (5 μg) or Mut genome [where Ser90 (TCT) codon of Sm t-
Ag is replaced with a stop codon (TAA), 5 μg] employing
lipofectin according to manufacturer's recommendations (Invi-
trogen, Carlsbad, CA). At 7d, 14d and 21d posttransfection, low
molecular weight DNA was isolated and processed for Dpn I
assay as described above. Moreover, in order to analyze the
effect of double mutant on viral replication cycle, SVG-A cells
(2×105 cells/T75 cm2 tissue culture flask) were transfected/
infected with JCV genome Mad-1 WT or double mutant (a
combination of Sm t-Ag stop mutant and a triple phosphoryla-
tion mutant of agnoprotein) (10 μg/flask), as described above.
Samples were then processed for either Dpn I assay or Western
blotting as indicated under related figure legends.
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